IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab TrialPhase 3, BE RADIANT ConferenceSPIN 2022 26 August, 2022 10:35
Bimekizumab superior to secukinumab in psoriasis Presented ByProf. Kristian Reich, University Medical Center Hamburg-Eppendorf, Germany TrialPhase 3, BE RADIANT ConferenceAAD VMX 2021 7 June, 2021 10:47